EI

249.5

-1.73%↓

SAN

81.41

-1.67%↓

SHL.DE

45.6

-1.68%↓

ARGX

583

-3.06%↓

PHIA

22.78

-1.17%↓

EI

249.5

-1.73%↓

SAN

81.41

-1.67%↓

SHL.DE

45.6

-1.68%↓

ARGX

583

-3.06%↓

PHIA

22.78

-1.17%↓

EI

249.5

-1.73%↓

SAN

81.41

-1.67%↓

SHL.DE

45.6

-1.68%↓

ARGX

583

-3.06%↓

PHIA

22.78

-1.17%↓

EI

249.5

-1.73%↓

SAN

81.41

-1.67%↓

SHL.DE

45.6

-1.68%↓

ARGX

583

-3.06%↓

PHIA

22.78

-1.17%↓

EI

249.5

-1.73%↓

SAN

81.41

-1.67%↓

SHL.DE

45.6

-1.68%↓

ARGX

583

-3.06%↓

PHIA

22.78

-1.17%↓

Search

Pharming Group NV

Atvērts

1.028 -2.74

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.021

Max

1.077

Galvenie mērījumi

By Trading Economics

Ienākumi

19M

4.7M

Pārdošana

14M

93M

EPS

-0.02

Peļņas marža

5.035

Darbinieki

404

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

81M

699M

Iepriekšējā atvēršanas cena

3.77

Iepriekšējā slēgšanas cena

1.028

Pharming Group NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. aug. 23:11 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

2025. g. 5. aug. 22:45 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23%

2025. g. 5. aug. 22:39 UTC

Peļņas

Great-West Lifeco Logs Lower 2Q Profit

2025. g. 5. aug. 21:32 UTC

Peļņas

Coupang Posts Higher 2Q Sales Due to Customer Growth

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

NFL to Take 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

2025. g. 5. aug. 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

2025. g. 5. aug. 23:40 UTC

Tirgus saruna

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

2025. g. 5. aug. 23:19 UTC

Tirgus saruna

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

2025. g. 5. aug. 23:03 UTC

Tirgus saruna
Peļņas

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

2025. g. 5. aug. 22:22 UTC

Peļņas

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

2025. g. 5. aug. 22:21 UTC

Peļņas

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

2025. g. 5. aug. 22:20 UTC

Peļņas

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

2025. g. 5. aug. 22:18 UTC

Peļņas

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

2025. g. 5. aug. 22:15 UTC

Peļņas

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

2025. g. 5. aug. 21:58 UTC

Peļņas

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

2025. g. 5. aug. 21:30 UTC

Peļņas

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

2025. g. 5. aug. 21:26 UTC

Peļņas

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

2025. g. 5. aug. 21:23 UTC

Peļņas

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

2025. g. 5. aug. 21:17 UTC

Peļņas

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Salīdzinājums

Cenas izmaiņa

Pharming Group NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.